[go: up one dir, main page]

WO2013066374A3 - Protection par l'humanine des neurones dopaminergiques - Google Patents

Protection par l'humanine des neurones dopaminergiques Download PDF

Info

Publication number
WO2013066374A3
WO2013066374A3 PCT/US2012/000535 US2012000535W WO2013066374A3 WO 2013066374 A3 WO2013066374 A3 WO 2013066374A3 US 2012000535 W US2012000535 W US 2012000535W WO 2013066374 A3 WO2013066374 A3 WO 2013066374A3
Authority
WO
WIPO (PCT)
Prior art keywords
dopaminergic neurons
humanin
protection
disease
methods
Prior art date
Application number
PCT/US2012/000535
Other languages
English (en)
Other versions
WO2013066374A2 (fr
Inventor
Radhika Muzumdar
Diana Casper
Rukmani LEKHRAJ
Original Assignee
Albert Einstein College Of Medicine Of Yeshiva University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Of Medicine Of Yeshiva University filed Critical Albert Einstein College Of Medicine Of Yeshiva University
Publication of WO2013066374A2 publication Critical patent/WO2013066374A2/fr
Publication of WO2013066374A3 publication Critical patent/WO2013066374A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des méthodes de traitement de la maladie de Parkinson, consistant à protéger les neurones dopaminergiques contre la neurotoxicité et à augmenter les niveaux de DJ-1 dans les neurones. L'invention concerne également des méthodes d'identification de traitements d'intérêt potentiel contre la maladie de Parkinson.
PCT/US2012/000535 2011-11-02 2012-11-02 Protection par l'humanine des neurones dopaminergiques WO2013066374A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554660P 2011-11-02 2011-11-02
US61/554,660 2011-11-02

Publications (2)

Publication Number Publication Date
WO2013066374A2 WO2013066374A2 (fr) 2013-05-10
WO2013066374A3 true WO2013066374A3 (fr) 2013-07-04

Family

ID=48192971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/000535 WO2013066374A2 (fr) 2011-11-02 2012-11-02 Protection par l'humanine des neurones dopaminergiques

Country Status (1)

Country Link
WO (1) WO2013066374A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080440A1 (fr) * 2022-10-12 2024-04-18 동아대학교 산학협력단 Composition pour la prévention ou le traitement de troubles neurodégénératifs, comprenant le peptide humanine utilisé comme principe actif

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233326A1 (en) * 2002-06-14 2005-10-20 Shuji Hinuma Novel screening method
US7371225B2 (en) * 2002-09-24 2008-05-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for convection enhanced delivery of therapeutic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050233326A1 (en) * 2002-06-14 2005-10-20 Shuji Hinuma Novel screening method
US7371225B2 (en) * 2002-09-24 2008-05-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for convection enhanced delivery of therapeutic agents

Also Published As

Publication number Publication date
WO2013066374A2 (fr) 2013-05-10

Similar Documents

Publication Publication Date Title
WO2011141823A3 (fr) Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
PH12014500767A1 (en) Compositions for the treatment of dry eye
CA2865011C (fr) Procedes et compositions permettant de traiter la maladie de huntington
WO2016037157A3 (fr) Ciblage de l'activité capn9/capns2 en tant que stratégie thérapeutique pour le traitement de la différentiation des myofibroblastes et des pathologies associées
IL237369B (en) N-]2-(6-fluoro-h1-indol-3-yl)ethyl]-3-(2, 2, 3, 3- tetrafluoropropoxy) benzylamine in combination with an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
EP2779564A4 (fr) Procédé et système destinés à authentifier l'identité d'un utilisateur et équipement utilisé lors de cette authentification
ZA201402049B (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2014058875A3 (fr) Polythérapies et leurs utilisations pour le traitement de troubles de la démyélinisation
WO2014089241A3 (fr) Profilage moléculaire pour cancer
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
TR201905683T4 (tr) Aşındırıcı presbiyopi için oftalmik formülasyon ve yöntem.
WO2012174338A3 (fr) Procédé de sélection d'indications thérapeutiques
HK1220980A1 (zh) 用於治療龐貝氏症的方法和組合物
WO2010118243A3 (fr) Utilisation d'antagonistes de il-27 pour traiter le lupus
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
WO2012173846A3 (fr) Macrocycles peptidomimétiques
WO2012135365A3 (fr) Systèmes et procédés destinés à être utilisés dans le traitement d'une déficience sensorielle
WO2012158672A3 (fr) Composés utilisés dans le traitement de la mucosite
WO2012154695A3 (fr) Traitement d'une maladie polykystique
EP3558340A4 (fr) Procédés d'utilisation de gm6 dans le diagnostic et le traitement de la maladie d'alzheimer
EP2558104A4 (fr) Procédé et composition ophtalmique pour traiter une maladie rétinienne
WO2013040251A3 (fr) Méthodes et compositions incluant mir-135b, permettant de faire la distinction entre un cancer du pancréas et une maladie pancréatique bénigne
WO2014004934A3 (fr) Compositions et procédés de traitement de la maladie d'alzheimer
WO2012170742A3 (fr) Traitement et prévention du cancer avec des antagonistes du hmgb1
HK1214517A1 (zh) 4-羟基-2-甲基-5-(丙-2-亚基)环己-3-烯甲醛用於预防及治疗认知、神经退行性或神经元疾病

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12846677

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12846677

Country of ref document: EP

Kind code of ref document: A2